PFS Without CNS disease at BL
PFS with CNS disease at BL
100
80
60
40
20
0
PFS rate (%)
0
6
12
18
27
24
21
3
9
15
1
Alectinib
Crizotinib
Time (months)
No. of patients at risk
40
28
22
12
63
48
28
16
5
3
80
63
89
75
89
74
100
80
60
40
20
0
PFS rate (%)
0
6
12
18
27
24
21
3
9
15
1
Alectinib
Crizotinib
Time (months)
No. of patients at risk
9
12
5
2
13
17
8
5
4
1
13
23
14
29
14
28
1
Alectinib (N=89) Crizotinib (N=75)
Event
24 (27.0%)
42 (56.0%)
Median [95% CI] 20.3 [17.5 ; -]
10.0 [8.2 ; 13.9]
P-Value
0.0001
HR [95% CI]*
0.37 [0.22 ; 0.62]
Alectinib (N=14) Crizotinib (N=29)
Event
1 (7.1%)
16 (55.2%)
Median [95% CI] - [- ; -]
10.2 [6.5 ; 14.2]
P-Value
0.0062
HR [95% CI]*
0.09 [0.01 ; 0.74]
Alectinib
Crizotinib
Alectinib
Crizotinib
1L ALECTINIB: J-ALEX
Kim Y-H, et al. WCLC 2016
